BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ito T, Lee L, Jensen RT. Treatment of symptomatic neuroendocrine tumor syndromes: recent advances and controversies. Expert Opin Pharmacother. 2016;17:2191-2205. [PMID: 27635672 DOI: 10.1080/14656566.2016.1236916] [Cited by in Crossref: 45] [Cited by in F6Publishing: 32] [Article Influence: 6.4] [Reference Citation Analysis]
Number Citing Articles
1 Ito T, Ramos-Alvarez I, Jensen RT. Successful Lifetime/Long-Term Medical Treatment of Acid Hypersecretion in Zollinger-Ellison Syndrome (ZES): Myth or Fact? Insights from an Analysis of Results of NIH Long-Term Prospective Studies of ZES. Cancers (Basel) 2023;15. [PMID: 36900170 DOI: 10.3390/cancers15051377] [Reference Citation Analysis]
2 Bevere M, Gkountakos A, Martelli FM, Scarpa A, Luchini C, Simbolo M. An Insight on Functioning Pancreatic Neuroendocrine Neoplasms. Biomedicines 2023;11. [PMID: 36830839 DOI: 10.3390/biomedicines11020303] [Reference Citation Analysis]
3 Bloemen H, Kneepkens K, Deraedt K, Ivanova A, Sergeant G, Mebis J, Van der Speeten K. Evaluation of quality of clinical management of neuroendocrine tumors. Cancer Innovation 2022;1:305-315. [DOI: 10.1002/cai2.41] [Reference Citation Analysis]
4 Yazdian A, Minuk J, Hemenway G, Upadhyaya N, Vaz CL. Occult Pulmonary Neuroendocrine Tumor Causing Severe Hyperparathyroidism: Diagnostic Challenges and Clinical Outcomes. AACE Clinical Case Reports 2022;8:210-216. [DOI: 10.1016/j.aace.2022.06.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Modica R, Liccardi A, Minotta R, Cannavale G, Benevento E, Colao A. Therapeutic strategies for patients with neuroendocrine neoplasms: current perspectives. Expert Rev Endocrinol Metab 2022;:1-15. [PMID: 35822906 DOI: 10.1080/17446651.2022.2099840] [Reference Citation Analysis]
6 Weber HC. Gastrointestinal regulatory peptides. Curr Opin Endocrinol Diabetes Obes 2022;29:167-8. [PMID: 35197424 DOI: 10.1097/MED.0000000000000719] [Reference Citation Analysis]
7 Siebenhüner AR, Langheinrich M, Friemel J, Schäfer N, Eshmuminov D, Lehmann K. Orchestrating Treatment Modalities in Metastatic Pancreatic Neuroendocrine Tumors-Need for a Conductor. Cancers (Basel) 2022;14:1478. [PMID: 35326628 DOI: 10.3390/cancers14061478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lee L, Ramos-Alvarez I, Jensen RT. Predictive Factors for Resistant Disease with Medical/Radiologic/Liver-Directed Anti-Tumor Treatments in Patients with Advanced Pancreatic Neuroendocrine Neoplasms: Recent Advances and Controversies. Cancers (Basel) 2022;14:1250. [PMID: 35267558 DOI: 10.3390/cancers14051250] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 O’brien SR, Pryma DA. Neuroendocrine Tumors: Therapy with 131I-MIBG. Nuclear Oncology 2022. [DOI: 10.1007/978-3-319-26067-9_93-1] [Reference Citation Analysis]
10 O’brien SR, Pryma DA. Neuroendocrine Tumors: Therapy with 131I-MIBG. Nuclear Oncology 2022. [DOI: 10.1007/978-3-031-05494-5_93] [Reference Citation Analysis]
11 German J, Burke LMB, Rowell JV. Clinical, Laboratory, and Radiological Diagnosis of Pancreatic Islet Cell Tumors. Diagnosis and Management of Endocrine Disorders in Interventional Radiology 2022. [DOI: 10.1007/978-3-030-87189-5_5] [Reference Citation Analysis]
12 . Viszeralchirurgie. FAP Allgemein- und Viszeralchirurgie 2022. [DOI: 10.1016/b978-3-437-23244-2.00005-7] [Reference Citation Analysis]
13 Subash N, Papali MM, Bahadur KP, Avanthika C, Jhaveri S, Thannir S, Joshi M, Valisekka SS. Recent Advances in the Diagnosis and Management of Carcinoid Syndrome. Dis Mon 2021;:101304. [PMID: 34972546 DOI: 10.1016/j.disamonth.2021.101304] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 de Ponthaud C, Menegaux F, Gaujoux S. Updated Principles of Surgical Management of Pancreatic Neuroendocrine Tumours (pNETs): What Every Surgeon Needs to Know. Cancers (Basel) 2021;13:5969. [PMID: 34885079 DOI: 10.3390/cancers13235969] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Тyshchenko АМ, Smachylo RM, Mushenko EV, Ivanenko OV. Carcinoid of small intestine - the cause of gastro-intestinal hemorrhage and acute ileus. KH 2021;88:94-97. [DOI: 10.26779/2522-1396.2021.5-6.94] [Reference Citation Analysis]
16 Xu J. Current treatments and future potential of surufatinib in neuroendocrine tumors (NETs). Ther Adv Med Oncol 2021;13:17588359211042689. [PMID: 34484432 DOI: 10.1177/17588359211042689] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
17 Kečkéš Š, Palaj J, Waczulíková I, Dyttert D, Mojtová E, Kováč G, Durdík Š. Pretreatment Levels of Chromogranin A and Neuron-specific Enolase in Patients With Gastroenteropancreatic Neuroendocrine Neoplasia. In Vivo 2021;35:2863-8. [PMID: 34410979 DOI: 10.21873/invivo.12574] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
18 de Herder WW, Feelders RA, Hofland J. Medical treatment of neuroendocrine neoplasms. Current Opinion in Endocrine and Metabolic Research 2021;18:139-144. [DOI: 10.1016/j.coemr.2021.03.019] [Reference Citation Analysis]
19 Hu Y, Ye Z, Wang F, Qin Y, Xu X, Yu X, Ji S. Role of Somatostatin Receptor in Pancreatic Neuroendocrine Tumor Development, Diagnosis, and Therapy. Front Endocrinol (Lausanne) 2021;12:679000. [PMID: 34093445 DOI: 10.3389/fendo.2021.679000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
20 Rodriguez-Freixinos V, Thawer A, Capdevila J, Ferone D, Singh S. Advanced Pancreatic Neuroendocrine Neoplasms: Which Systemic Treatment Should I Start With? Curr Oncol Rep 2021;23:80. [PMID: 33937962 DOI: 10.1007/s11912-021-01071-5] [Reference Citation Analysis]
21 Orsi F, Bonomo G. Locoregional Therapies of NEN. Neuroendocrine Neoplasia Management 2021. [DOI: 10.1007/978-3-030-72830-4_10] [Reference Citation Analysis]
22 Hodge C, Fahy BN. Palliative Interventions for Metastatic Neuroendocrine Tumors. Neuroendocrine Tumors 2021. [DOI: 10.1007/978-3-030-62241-1_19] [Reference Citation Analysis]
23 Ito T, Jensen RT. Perspectives on the current pharmacotherapeutic strategies for management of functional neuroendocrine tumor syndromes. Expert Opin Pharmacother 2021;22:685-93. [PMID: 33131345 DOI: 10.1080/14656566.2020.1845651] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Couper R. Future of paediatric gastroenterology. J Paediatr Child Health 2020;56:1674-6. [PMID: 33197984 DOI: 10.1111/jpc.15023] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
25 Jonica ER, Wagh MS. Endoscopic treatment of symptomatic insulinoma with a new EUS-guided radiofrequency ablation device. VideoGIE 2020;5:483-485. [DOI: 10.1016/j.vgie.2020.05.028] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
26 Pusceddu S, Rossi RE, Torchio M, Prinzi N, Niger M, Coppa J, Giacomelli L, Sacco R, Facciorusso A, Corti F, Raimondi A, Prisciandaro M, Colombo E, Beninato T, Del Vecchio M, Milione M, Di Bartolomeo M, de Braud F. Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. J Clin Med 2020;9:E2468. [PMID: 32752158 DOI: 10.3390/jcm9082468] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
27 Megdanova-Chipeva VG, Lamarca A, Backen A, McNamara MG, Barriuso J, Sergieva S, Gocheva L, Mansoor W, Manoharan P, Valle JW. Systemic Treatment Selection for Patients with Advanced Pancreatic Neuroendocrine Tumours (PanNETs). Cancers (Basel) 2020;12:E1988. [PMID: 32708210 DOI: 10.3390/cancers12071988] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
28 Businello G, Dal Pozzo CA, Sbaraglia M, Mastracci L, Milione M, Saragoni L, Grillo F, Parente P, Remo A, Bellan E, Cappellesso R, Pennelli G, Michelotto M, Fassan M. Histopathological landscape of rare oesophageal neoplasms. World J Gastroenterol 2020; 26(27): 3865-3888 [PMID: 32774063 DOI: 10.3748/wjg.v26.i27.3865] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
29 Peri M, Fazio N. Clinical Evaluation of Everolimus in the Treatment of Neuroendocrine Tumors of the Lung: Patient Selection and Special Considerations. A Systematic and Critical Review of the Literature. Lung Cancer (Auckl) 2020;11:41-52. [PMID: 32753993 DOI: 10.2147/LCTT.S249928] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
30 Pavel M, Öberg K, Falconi M, Krenning EP, Sundin A, Perren A, Berruti A; ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2020;31:844-60. [PMID: 32272208 DOI: 10.1016/j.annonc.2020.03.304] [Cited by in Crossref: 254] [Cited by in F6Publishing: 279] [Article Influence: 84.7] [Reference Citation Analysis]
31 Rashidian N, Alseidi A, Kirks RC. Cancers Metastatic to the Liver. Surg Clin North Am 2020;100:551-63. [PMID: 32402300 DOI: 10.1016/j.suc.2020.02.005] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
32 Yuan G, Zhan C, Zhu D, Xie H, Wei T, Lu T, Yang Y, Zhu Y, Wang Q. Population-based analysis of esophageal large cell neuroendocrine carcinoma between 2004 and 2015. J Thorac Dis 2019;11:5480-8. [PMID: 32030267 DOI: 10.21037/jtd.2019.11.34] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
33 Ishida H, Lam AK. Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification. Critical Reviews in Oncology/Hematology 2020;145:102835. [DOI: 10.1016/j.critrevonc.2019.102835] [Cited by in Crossref: 16] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
34 Lee L, Ito T, Jensen RT. Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies. Expert Rev Anticancer Ther. 2019;19:1029-1050. [PMID: 31738624 DOI: 10.1080/14737140.2019.1693893] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 7.5] [Reference Citation Analysis]
35 Kong G, Hicks RJ. Peptide Receptor Radiotherapy: Current Approaches and Future Directions. Curr Treat Options in Oncol 2019;20. [DOI: 10.1007/s11864-019-0677-7] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
36 Zubiri L, Bilbao JI, Rodríguez J, Sangro B. Selective internal radiation therapy: an effective treatment for hormonal syndromes in pancreatic neuroendocrine tumors. Hepat Oncol 2018;5:HEP09. [PMID: 31293777 DOI: 10.2217/hep-2017-0025] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
37 Hopper AD, Jalal M, Munir A. Recent advances in the diagnosis and management of pancreatic neuroendocrine tumours. Frontline Gastroenterol 2019;10:269-74. [PMID: 31290854 DOI: 10.1136/flgastro-2018-101006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
38 Jin XF, Spampatti MP, Spitzweg C, Auernhammer CJ. Supportive therapy in gastroenteropancreatic neuroendocrine tumors: Often forgotten but important. Rev Endocr Metab Disord 2018;19:145-58. [PMID: 29464446 DOI: 10.1007/s11154-018-9443-6] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
39 Ito T, Lee L, Jensen RT. Carcinoid-syndrome: recent advances, current status and controversies. Curr Opin Endocrinol Diabetes Obes 2018;25:22-35. [PMID: 29120923 DOI: 10.1097/MED.0000000000000376] [Cited by in Crossref: 58] [Cited by in F6Publishing: 65] [Article Influence: 14.5] [Reference Citation Analysis]
40 Goretzki PE, Mogl MT, Akca A, Pratschke J. Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract. Rev Endocr Metab Disord 2018;19:169-78. [DOI: 10.1007/s11154-018-9469-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.4] [Reference Citation Analysis]
41 Lee L, Ito T, Jensen RT. Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies. Expert Rev Anticancer Ther 2018;18:837-60. [PMID: 29973077 DOI: 10.1080/14737140.2018.1496822] [Cited by in Crossref: 42] [Cited by in F6Publishing: 28] [Article Influence: 8.4] [Reference Citation Analysis]
42 Moody TW, Ramos-Alvarez I, Jensen RT. Neuropeptide G Protein-Coupled Receptors as Oncotargets. Front Endocrinol (Lausanne) 2018;9:345. [PMID: 30008698 DOI: 10.3389/fendo.2018.00345] [Cited by in Crossref: 29] [Cited by in F6Publishing: 32] [Article Influence: 5.8] [Reference Citation Analysis]
43 Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
44 Ito T, Jensen RT. Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management. Curr Opin Endocrinol Diabetes Obes 2017;24:15-24. [PMID: 27875420 DOI: 10.1097/MED.0000000000000300] [Cited by in Crossref: 13] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
45 Weber HC. Editorial overview. Current Opinion in Endocrinology & Diabetes and Obesity 2018;25:1-2. [DOI: 10.1097/med.0000000000000384] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
46 Jensen RT. Gastrointestinal Neuroendocrine Tumor Syndromes (GI NETS). Encyclopedia of Endocrine Diseases 2018. [DOI: 10.1016/b978-0-12-801238-3.95870-7] [Reference Citation Analysis]
47 Sundaresan S, Kang AJ, Merchant JL. Pathophysiology of Gastric NETs: Role of Gastrin and Menin. Curr Gastroenterol Rep 2017;19:32. [PMID: 28608155 DOI: 10.1007/s11894-017-0572-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
48 Cangiano B, Fatti LM, Persani L, Vitale G. Nuovi farmaci a bersaglio molecolare nei tumori neuroendocrini gastroenteropancreatici. L'Endocrinologo 2017;18:280-284. [DOI: 10.1007/s40619-017-0359-2] [Reference Citation Analysis]
49 Ma Z, Cai H, Cui Y. Progress in the treatment of esophageal neuroendocrine carcinoma. Tumour Biol. 2017;39:1010428317711313. [PMID: 28653897 DOI: 10.1177/1010428317711313] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]